U.S. flag

An official website of the United States government

Format
Items per page
Sort by

Send to:

Choose Destination

Links from GEO DataSets

Items: 9

1.
Full record GDS4047

Chronic myelogenous leukemia CD34+CD38- cells response to histone deacetylase inhibitor analog and imatinib mesylate

Analysis of sorted chronic myelogenous leukemia (CML) CD34+CD38- cells cultured with histone deacetylase inhibitor analog LBH589 (LBH) and/or BCR-ABL tyrosine kinase inhibitor imatinib mesylate (IM). Results provide insight into molecular mechanisms underlying treatment of CML with LBH and IM.
Organism:
Homo sapiens
Type:
Expression profiling by array, transformed count, 4 agent sets
Platform:
GPL570
Series:
GSE20876
12 Samples
Download data: CEL
2.

Effective Targeting of Quiescent Chronic Myelogenous Leukemia Stem Cells by Histone Deacetylase Inhibitors in Combination with Imatinib Mesylate

(Submitter supplied) We investigated the ability of HDAC inhibitors (HDACi) to target CML stem cells. Treatment with HDACi combined with IM effectively induced apoptosis in quiescent CML progenitors resistant to elimination by IM alone, and eliminated CML stem cells capable of engrafting immunodeficient mice. In vivo administration of HDACi with IM markedly diminished LSC in a transgenic mouse model of CML. The interaction of IM and HDACi inhibited genes regulating hematopoietic stem cell maintenance and survival. more...
Organism:
Homo sapiens
Type:
Expression profiling by array
Dataset:
GDS4047
Platform:
GPL570
12 Samples
Download data: CEL
Series
Accession:
GSE20876
ID:
200020876
3.

Physiologic Hypoxia Promotes Maintenance of CML Stem Cells Despite Effective BCR−ABL1 Inhibition

(Submitter supplied) ABL1 kinase inhibitors such as imatinib mesylate (IM) are effective in managing chronic myelogenous leukemia (CML) but incapable of eliminating leukemia stem cells (LSCs), suggesting that kinase−independent pathways support LSC survival. Given that the bone marrow hypoxic microenvironment supports hematopoietic stem cells, we investigated if hypoxia similarly contributes to LSC persistence. Importantly, we found that while BCR−ABL1 kinase remained effectively inhibited by IM under hypoxia, apoptosis became partially suppressed. more...
Organism:
Homo sapiens
Type:
Expression profiling by array
Platform:
GPL10558
24 Samples
Download data: TXT
Series
Accession:
GSE48294
ID:
200048294
4.

Real-time quantitative PCR analysis of microRNAs in CML stem cells

(Submitter supplied) Lin-CD34+CD38+ and Lin-CD34-CD38- cells were isolated from 5 CML patients at diagnosis and 4 healthy donors.
Organism:
Homo sapiens
Type:
Expression profiling by RT-PCR
Platform:
GPL19066
18 Samples
Download data: TXT
Series
Accession:
GSE90773
ID:
200090773
5.

Chronic myelogenous leukemia hematopoietic stem cells

(Submitter supplied) We show the molecular and functional characterization of a novel population of lineage-negative CD34-negative (Lin- CD34-) hematopoietic stem cells (HSCs) from chronic myelogenous leukemia (CML) patients at diagnosis. Molecular caryotyping and quantitative analysis of BCR/ABL transcript demonstrated that about one third of CD34- was leukemic. CML CD34- cells showed kinetic quiescence and limited clonogenic capacity. more...
Organism:
Homo sapiens
Type:
Expression profiling by array
Platform:
GPL8300
6 Samples
Download data: CEL, CHP
Series
Accession:
GSE11675
ID:
200011675
6.

Gene expression profiling of Imatinib and PD166326 resistant cell lines

(Submitter supplied) A comparison between parental K562 cells (CML) and two clones derived from this cell line : ImaR and PDR which are resistant against Imatinib mesylate and PD166326 respectively , two inhibitors of BCR-ABL. Keywords: gene expression, comparison
Organism:
Homo sapiens
Type:
Expression profiling by array
Platform:
GPL1456
6 Samples
Download data: GPR
Series
Accession:
GSE10382
ID:
200010382
7.

Gene expression analysis of chronic myeloid leukemic stem cells and progenitor cells from untreated and imatinib-treated CML-like mice

(Submitter supplied) To understand gene expression signatures of CML stem cells underlying imatinib-resistance, we compared transcriptomes of CML stem and progenitor cells from vehicle and imatinib-treated CML mice, respectively.
Organism:
Mus musculus
Type:
Expression profiling by high throughput sequencing
Platform:
GPL19057
12 Samples
Download data: TXT
Series
Accession:
GSE175323
ID:
200175323
8.

Transcriptome profiling of fenretinide-treated and untreated CD34+ cells from 4 CML patients

(Submitter supplied) Imatinib, as the first-line agent of chronic myeloid leukemia (CML), is ineffective in eradicating CML stem/progenitor cells, thus unable to prevent late relapse. Here we present data indicating that fenretinide preferentially targets CD34+ CML cells and enhances the efficacy of imatinib in CML. As tested by colony forming cell assays, both number and size of total colonies derived from CD34+ CML cells were significantly reduced by fenretinide, and by combining fenretinide with imatinib. more...
Organism:
Homo sapiens
Type:
Expression profiling by array
Platform:
GPL570
8 Samples
Download data: CEL
Series
Accession:
GSE17480
ID:
200017480
9.

Treatment of primary acute myelogenous leukemia (AML) specimens with parthenolide (PTL)

(Submitter supplied) The effects of 7.5 micromolar parthenolide (PTL) were assessed on primary CD34+ acute myelogenous leukemia specimens obtained from 12 patients. Keywords: drug response, gene expression search agent
Organism:
Homo sapiens
Type:
Expression profiling by array
Platform:
GPL570
24 Samples
Download data: CEL
Series
Accession:
GSE7538
ID:
200007538
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

db=gds|term=|query=1|qty=3|blobid=MCID_66633e6dbb845b085bc0d2a9|ismultiple=true|min_list=5|max_list=20|def_tree=20|def_list=|def_view=|url=/Taxonomy/backend/subset.cgi?|trace_url=/stat?
   Taxonomic Groups  [List]
Tree placeholder
    Top Organisms  [Tree]

Find related data

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Support Center